HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session ...Middle East

CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a...

Hence then, the article about harmoni 6 demonstrates significant overall survival benefit hr 0 66 ivonescimab plus chemotherapy superior to pd 1 plus chemotherapy in first line sq nsclc landmark results to be presented at asco 2026 plenary session was published today ( Sunday 31/05/2026 - 04:05 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session )

Also on site :

• Trump pushes for last-minute changes to Iran peace draft – media
• Jif Peanut Butter's Brand-New Release Is an Epic Twist on a Classic — 'Two Pantry Legends'
• Nine in 10 parents back a social media ban – but could Britain make it work?